The impact of genetic variation on sensitivity to opioid analgesics in patients with postoperative pain: a systematic review and meta-analysis.

BACKGROUND Individual response to opioid analgesics varies among patients. OBJECTIVE This study sought to clarify the impact of distinct genetic variations on pain, opioid consumption, and opioid side effects in patients with postoperative pain. STUDY DESIGN A systematic review and meta-analysis of associations between genetic single-nucleotide polymorphisms (SNPs) and opioids used for acute postoperative pain. SETTING This meta-analysis examined all studies involving an association between genetic polymorphisms and the analgesic efficacy or clinical outcome of opioid analgesics for postoperative pain. METHODS A literature search was performed up to January 31, 2014, using the PubMed, EMBase, ISI Web of Science, and Cochrane Library databases. RESULTS Fifty-nine studies were included in this systematic review, and 23 studies (a total of 5,902 patients) were included in the final meta-analysis. The results showed that human μ-opioid receptor gene (OPRM1) 118G allele variant carriers consumed more opioids for analgesia (SMD = -0.17, 95% CI = [-0.25, -0.10], P < 0.00001), but reported higher pain scores (MD = -0.11, 95% CI = [-0.17, -0.04], P = 0.002) and less nausea and vomiting (odds ratio = 1.30, 95% CI = [1.08, 1.55], P = 0.005) than the homozygous 118AA patients during the first 24 hour but not the 48 hour postoperative period. Moreover, CYP3A4*1G carriers consumed less opioids than homozygous CYP3A4*1/*1 patients during the first 24 hours postoperative period (MD = 45.12, 95% CI = [36.17, 54.06], P < 0.00001). No significant differences were found in CYP3A5*3, ABCB1 C3435T, and G2477T/A genetic polymorphisms. LIMITATIONS Some potential non-genetic factors can modify the effects of gene SNP on pain and opioid consumption during the postoperative period, such as age, gender, mood, anxiety, and drug-drug interactions. But further analyses could not be performed in the present meta-analysis due to limited information. CONCLUSION The results indicate that among the genetic SNPs we studied which include those affecting analgesic drug metabolism, transport of analgesic agents across the blood-brain barrier, and their activity at target receptors and ion channels and in the modulation of neurotransmitter pathways, the A118G allele variant of OPRM1 has the most potent influence on pain management of postoperative patients. Opioid receptor gene information may provide valuable information for clinicians to properly manage the analgesic use of opioids individually for better pain management.

[1]  Andrew D. Johnson,et al.  Allelic Expression Imbalance of Human mu Opioid Receptor (OPRM1) Caused by Variant A118G* , 2005, Journal of Biological Chemistry.

[2]  H. Dengler,et al.  PHARMACOKINETICS AND DISPOSITION , 1997 .

[3]  R. Houde,et al.  Analgesic studies of codeine and oxycodone in patients with cancer. I. Comparisons of oral with intramuscular codeine and of oral with intramuscular oxycodone. , 1978, The Journal of pharmacology and experimental therapeutics.

[4]  Andrew A Somogyi,et al.  Pharmacogenetics of Opioids , 2007, Clinical pharmacology and therapeutics.

[5]  Hai-Yan Zhou,et al.  Polymorphism of the micro-opioid receptor gene (OPRM1 118A>G) affects fentanyl-induced analgesia during anesthesia and recovery. , 2009, Molecular diagnosis & therapy.

[6]  Y. Daali,et al.  Codeine intoxication associated with ultrarapid CYP2D6 metabolism. , 2004, The New England journal of medicine.

[7]  G. Baggerman,et al.  Human White Blood Cells Synthesize Morphine: CYP2D6 Modulation1 , 2005, The Journal of Immunology.

[8]  J. Lötsch,et al.  Increased CNS uptake and enhanced antinociception of morphine‐6‐glucuronide in rats after inhibition of P‐glycoprotein , 2002, Journal of neurochemistry.

[9]  M. Yahr,et al.  Catechol‐O‐methyltransferase inhibition increases striatal L‐dopa and dopamine , 1992, Neurology.

[10]  J. Belknap,et al.  The genetics of pain and pain inhibition. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[11]  M. Moal,et al.  Opiate tolerance to daily heroin administration: an apparent phenomenon associated with enhanced pain sensitivity , 1999, Neuroscience.

[12]  D. Campa,et al.  Association of ABCB1/MDR1 and OPRM1 Gene Polymorphisms With Morphine Pain Relief , 2008, Clinical pharmacology and therapeutics.

[13]  I. Sora,et al.  Analgesic requirements after major abdominal surgery are associated with OPRM1 gene polymorphism genotype and haplotype. , 2008, Pharmacogenomics.

[14]  J A Tischfield,et al.  Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[15]  T. Oyama,et al.  Functional effects of nonsynonymous polymorphisms in the human TRPV1 gene. , 2007, American journal of physiology. Renal physiology.

[16]  Y. Kolesnikov,et al.  Combined Catechol-O-Methyltransferase and &mgr;-Opioid Receptor Gene Polymorphisms Affect Morphine Postoperative Analgesia and Central Side Effects , 2011, Anesthesia and analgesia.

[17]  S. Snyder,et al.  Properties of opiate-receptor binding in rat brain. , 1973, Proceedings of the National Academy of Sciences of the United States of America.

[18]  Xueyin Shi,et al.  Effects of OPRM1 A118G polymorphism on epidural analgesia with fentanyl during labor: a meta-analysis. , 2013, Genetic testing and molecular biomarkers.

[19]  Karamarie Fecho,et al.  Catechol-O-methyltransferase inhibition increases pain sensitivity through activation of both beta2- and beta3-adrenergic receptors. , 2007, Pain.

[20]  Raymond L. White,et al.  Functional characterization of human variants of the mu-opioid receptor gene , 2009, Proceedings of the National Academy of Sciences.

[21]  S. Kaasa,et al.  Genetic variation in the Catechol-O-Methyltransferase (COMT) gene and morphine requirements in cancer patients with pain , 2008, Molecular pain.

[22]  A. Markham,et al.  Fine mapping of the human 5-HTR2a gene to chromosome 13q14 and identification of two highly polymorphic linked markers suitable for association studies in psychiatric disorders. , 1997, Genetic testing.

[23]  S. H. Gan,et al.  Cytochrome P450 3A4 genetic polymorphisms and post‐operative fentanyl requirements , 2012, Journal of clinical pharmacy and therapeutics.

[24]  S. Govoni,et al.  Genetic variability at COMT but not at OPRM1 and UGT2B7 loci modulates morphine analgesic response in acute postoperative pain , 2013, European Journal of Clinical Pharmacology.

[25]  A. Hoeft,et al.  Impact of CYP2D6 genotype on postoperative tramadol analgesia , 2003, Pain.

[26]  A. Gaedigk,et al.  The CYP2D6 Activity Score: Translating Genotype Information into a Qualitative Measure of Phenotype , 2008, Clinical pharmacology and therapeutics.

[27]  R Kucherlapati,et al.  Association of codon 108/158 catechol-O-methyltransferase gene polymorphism with the psychiatric manifestations of velo-cardio-facial syndrome. , 1996, American journal of medical genetics.

[28]  P. Lund,et al.  A stop codon mutation in SCN9A causes lack of pain sensation. , 2007, Human molecular genetics.

[29]  S. H. Lee,et al.  Association of ABCB1 polymorphisms with the efficacy of ondansetron for postoperative nausea and vomiting , 2010, Anaesthesia.

[30]  Wei Zhang,et al.  Influence of CYP3A5*3 polymorphism and interaction between CYP3A5*3 and CYP3A4*1G polymorphisms on post-operative fentanyl analgesia in Chinese patients undergoing gynaecological surgery , 2011, European journal of anaesthesiology.

[31]  K. Brøsen,et al.  Impact of the CYP2D6 genotype on post‐operative intravenous oxycodone analgesia , 2010, Acta anaesthesiologica Scandinavica.

[32]  J. Shih,et al.  The human 5-HT2 receptor is encoded by a multiple intron-exon gene. , 1992, Brain research. Molecular brain research.

[33]  P. Albert,et al.  5-HT1A Receptors, Gene Repression, and Depression: Guilt by Association , 2004, The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry.

[34]  M. Le Moal,et al.  Progressive Enhancement of Delayed Hyperalgesia Induced by Repeated Heroin Administration: A Sensitization Process , 2001, The Journal of Neuroscience.

[35]  J. Lötsch,et al.  Analgesic effects of morphine and morphine‐6‐glucuronide in a transcutaneous electrical pain model in healthy volunteers , 2003, Clinical pharmacology and therapeutics.

[36]  G. Elmer,et al.  Genetic variance in nociception and its relationship to the potency of morphine-induced analgesia in thermal and chemical tests , 1998, Pain.

[37]  J. Fujimoto,et al.  The metabolic fate of codeine in man. , 1955, The Journal of pharmacology and experimental therapeutics.

[38]  B. Jawan,et al.  Human Opioid Receptor A118G Polymorphism Affects Intravenous Patient-controlled Analgesia Morphine Consumption after Total Abdominal Hysterectomy , 2006, Anesthesiology.

[39]  A. Hofman,et al.  A functional polymorphism in the catechol-O-methyltransferase gene is associated with osteoarthritis-related pain. , 2009, Arthritis and rheumatism.

[40]  J. Lötsch,et al.  The polymorphism A118G of the human mu-opioid receptor gene decreases the pupil constrictory effect of morphine-6-glucuronide but not that of morphine. , 2002, Pharmacogenetics.

[41]  K. Preston,et al.  Abuse potential and pharmacological comparison of tramadol and morphine. , 1991, Drug and alcohol dependence.

[42]  I. Sora,et al.  Mu opiate receptor gene dose effects on different morphine actions: evidence for differential in vivo mu receptor reserve. , 2001, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.

[43]  A. Concejero,et al.  Association of mu-opioid receptor gene polymorphism (A118G) with variations in morphine consumption for analgesia after total knee arthroplasty. , 2006, Acta anaesthesiologica Scandinavica.

[44]  Jörn Lötsch,et al.  Genetic modulation of the pharmacological treatment of pain. , 2009, Pharmacology & therapeutics.

[45]  P. Männistö,et al.  Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors. , 1999, Pharmacological reviews.

[46]  J. White.  Pleasure into pain: the consequences of long-term opioid use. , 2004, Addictive behaviors.

[47]  Ji-Young Park,et al.  OPRM1 A118G Gene Variant and Postoperative Opioid Requirement: A Systematic Review and Meta-analysis , 2014, Anesthesiology.

[48]  B. Mets,et al.  A Genetic Association Study of the Functional A118G Polymorphism of the Human &mgr;-Opioid Receptor Gene in Patients with Acute and Chronic Pain , 2006, Anesthesia and analgesia.

[49]  Yuangan Wu,et al.  Two novel SCN9A gene heterozygous mutations may cause partial deletion of pain perception. , 2011, Pain medicine.

[50]  K. Peck,et al.  Screening CYP3A single nucleotide polymorphisms in a Han Chinese population with a genotyping chip. , 2005, Pharmacogenomics.

[51]  M. Vickers,et al.  Tramadol: pain relief by an opioid without depression of respiration , 1992, Anaesthesia.

[52]  J. Lötsch,et al.  The μ-opioid receptor gene polymorphism 118A>G depletes alfentanil-induced analgesia and protects against respiratory depression in homozygous carriers , 2006 .

[53]  H. Lu,et al.  Association of human μ‐opioid receptor gene polymorphism A118G with fentanyl analgesia consumption in Chinese gynaecological patients , 2010, Anaesthesia.

[54]  D. Rujescu,et al.  HTR2C and HTR1A gene variants in German and Italian suicide attempters and completers , 2007, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[55]  A. Paterson,et al.  Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. , 2000, Pharmacogenetics.

[56]  H. Li,et al.  Effect of CYP3A4*1G on the fentanyl consumption for intravenous patient‐controlled analgesia after total abdominal hysterectomy in Chinese Han population , 2012, Journal of clinical pharmacy and therapeutics.

[57]  M. Morris,et al.  First Evidence of a Polygenic Susceptibility to Pain in a Pediatric Cohort , 2013, Anesthesia and analgesia.

[58]  B. Emanuel,et al.  Chromosomal mapping of the human catechol-O-methyltransferase gene to 22q11.1----q11.2. , 1992, Genomics.

[59]  John N. Wood,et al.  SCN9A Mutations in Paroxysmal Extreme Pain Disorder: Allelic Variants Underlie Distinct Channel Defects and Phenotypes , 2006, Neuron.

[60]  K. Candiotti,et al.  Single-nucleotide polymorphism C3435T in the ABCB1 gene is associated with opioid consumption in postoperative pain. , 2013, Pain medicine.

[61]  David B Reichling,et al.  The fundamental unit of pain is the cell. , 2013, Pain.

[62]  S. Joel,et al.  Clinical response to morphine in cancer patients and genetic variation in candidate genes , 2005, The Pharmacogenomics Journal.

[63]  E. Madenci,et al.  Association of T102C polymorphism of the 5-HT2A receptor gene with pyschiatric status in fibromyalgia syndrome , 2001, Rheumatology International.

[64]  Li Li,et al.  The correlation between post-operative fentanyl requirements and μ-opioid receptor gene A118G polymorphism in patients undergoing radical gastrectomy , 2013, Experimental and therapeutic medicine.

[65]  P. Blier,et al.  Activation of 5-HT2A receptors potentiates pain produced by inflammatory mediators , 1996, Neuropharmacology.

[66]  J. Lasker,et al.  Metabolism of fentanyl, a synthetic opioid analgesic, by human liver microsomes. Role of CYP3A4. , 1996, Drug metabolism and disposition: the biological fate of chemicals.

[67]  D. Nelson,et al.  Cytochrome P450 nomenclature, 2004. , 2006, Methods in molecular biology.

[68]  Dong Huang,et al.  Effect of CYP3A4*18B polymorphisms and interactions with OPRM1 A118G on postoperative fentanyl requirements in patients undergoing radical gastrectomy. , 2013, Molecular medicine reports.

[69]  J. Micó,et al.  The role of 5-HT1A receptors in research strategy for extensive pain treatment. , 2006, Current topics in medicinal chemistry.

[70]  S. Schulz,et al.  Effect of the A118G polymorphism on binding affinity, potency and agonist‐mediated endocytosis, desensitization, and resensitization of the human mu‐opioid receptor , 2004, Journal of neurochemistry.

[71]  S. Dib-Hajj,et al.  NaN, a novel voltage-gated Na channel, is expressed preferentially in peripheral sensory neurons and down-regulated after axotomy. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[72]  J. Lötsch,et al.  Genetic Predictors of the Clinical Response to Opioid Analgesics , 2004, Clinical pharmacokinetics.

[73]  S. Kaasa,et al.  The 118 A > G polymorphism in the human µ‐opioid receptor gene may increase morphine requirements in patients with pain caused by malignant disease , 2004, Acta anaesthesiologica Scandinavica.

[74]  I. Sora,et al.  Association between OPRM1 gene polymorphisms and fentanyl sensitivity in patients undergoing painful cosmetic surgery , 2009, PAIN®.

[75]  S. Halegoua,et al.  Identification of PN1, a predominant voltage-dependent sodium channel expressed principally in peripheral neurons. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[76]  E. Tan,et al.  Influence of mu-opioid receptor variant on morphine use and self-rated pain following abdominal hysterectomy. , 2013, The journal of pain : official journal of the American Pain Society.

[77]  R. D. du Bois,et al.  No pain relief from morphine? Individual variation in sensitivity to morphine and the need to switch to an alternative opioid in cancer patients. , 2006, Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer.

[78]  D. Vlahov,et al.  Opioid Receptor Polymorphism A118G Associated with Clinical Severity in a Drug Overdose Population , 2013, Journal of Medical Toxicology.

[79]  C. Woods,et al.  Painful and painless channelopathies , 2014, The Lancet Neurology.

[80]  Allele and genotype frequencies of the polymorphic cytochrome P450 genes (CYP1A1, CYP3A4, CYP3A5, CYP2C9 and CYP2C19) in the Jordanian population , 2012, Molecular Biology Reports.

[81]  R Todd Ogden,et al.  Higher 5-HT1A Receptor Binding Potential During a Major Depressive Episode Predicts Poor Treatment Response: Preliminary Data from a Naturalistic Study , 2006, Neuropsychopharmacology.

[82]  Hui Zhang,et al.  Effect of the CYP2D6*10 C188T polymorphism on postoperative tramadol analgesia in a Chinese population , 2006, European Journal of Clinical Pharmacology.

[83]  Y. Teo,et al.  Ethnicity and OPRM variant independently predict pain perception and patient-controlled analgesia usage for post-operative pain , 2009, Molecular pain.

[84]  A. M. Rush,et al.  A single sodium channel mutation produces hyper- or hypoexcitability in different types of neurons. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[85]  R. Fillingim,et al.  The A118G single nucleotide polymorphism of the mu-opioid receptor gene (OPRM1) is associated with pressure pain sensitivity in humans. , 2005, The journal of pain : official journal of the American Pain Society.

[86]  A. Dahan,et al.  Pharmacodynamic Effect of Morphine-6-glucuronide versus Morphine on Hypoxic and Hypercapnic Breathing in Healthy Volunteers , 2003, Anesthesiology.

[87]  A. Satterfield,et al.  TREATMENT , 1924, California and western medicine.

[88]  K. Ikeda,et al.  Diversity of opioid requirements for postoperative pain control following oral surgery--is it affected by polymorphism of the μ-opioid receptor? , 2010, Anesthesia progress.

[89]  С.,et al.  The Cell , 1997, Nature Medicine.

[90]  Neelima Khairatkar-Joshi,et al.  TRPV1 antagonists: the challenges for therapeutic targeting. , 2009, Trends in molecular medicine.

[91]  Q. Kan,et al.  Study of the OPRM1 A118G genetic polymorphism associated with postoperative nausea and vomiting induced by fentanyl intravenous analgesia. , 2011, Minerva anestesiologica.

[92]  W. Maixner,et al.  Genetic basis for individual variations in pain perception and the development of a chronic pain condition. , 2005, Human molecular genetics.

[93]  A. Patapoutian,et al.  Nociceptors: the sensors of the pain pathway. , 2010, The Journal of clinical investigation.

[94]  M. Schwarz,et al.  The T102C Polymorphism of the 5-HT2A-Receptor Gene in Fibromyalgia , 1999, Neurobiology of Disease.

[95]  E. Kharasch,et al.  Fentanyl metabolism by human hepatic and intestinal cytochrome P450 3A4: implications for interindividual variability in disposition, efficacy, and drug interactions. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[96]  A. Gottschalk,et al.  Natural Variation in the &mgr;-opioid Gene OPRM1 Predicts Increased Pain on Third Day After Thoracotomy , 2012, The Clinical journal of pain.

[97]  Lin He,et al.  Differences in CYP3A41G genotype distribution and haplotypes of CYP3A4, CYP3A5 and CYP3A7 in 3 Chinese populations. , 2007, Clinica chimica acta; international journal of clinical chemistry.

[98]  D. Andersson,et al.  TRP channel antagonists for pain--opportunities beyond TRPV1. , 2009, Current opinion in investigational drugs.

[99]  R. Fimmers,et al.  Antagonistic effects of ondansetron and tramadol? A randomized placebo and active drug controlled study. , 2010, The journal of pain : official journal of the American Pain Society.

[100]  G. Uhl,et al.  Human mu opiate receptor. cDNA and genomic clones, pharmacologic characterization and chromosomal assignment. , 1994, FEBS letters.

[101]  C. Eap,et al.  ABCB1 and cytochrome P450 genotypes and phenotypes: Influence on methadone plasma levels and response to treatment , 2006, Clinical pharmacology and therapeutics.

[102]  Jae-Gook Shin,et al.  Effects of genetic polymorphisms of OPRM1, ABCB1, CYP3A4/5 on postoperative fentanyl consumption in Korean gynecologic patients. , 2013, International journal of clinical pharmacology and therapeutics.

[103]  Y. Teo,et al.  A118G Single Nucleotide Polymorphism of Human &mgr;-Opioid Receptor Gene Influences Pain Perception and Patient-controlled Intravenous Morphine Consumption after Intrathecal Morphine for Postcesarean Analgesia , 2008, Anesthesiology.

[104]  J. Blouin,et al.  Genetic variability of the μ-opioid receptor influences intrathecal fentanyl analgesia requirements in laboring women , 2008, PAIN.

[105]  Yuangan Wu,et al.  Impact of CYP3A4*1G polymorphism on metabolism of fentanyl in Chinese patients undergoing lower abdominal surgery. , 2011, Clinica chimica acta; international journal of clinical chemistry.

[106]  W. Maixner,et al.  Catechol-O-methyltransferase gene polymorphisms are associated with multiple pain-evoking stimuli , 2006, Pain.

[107]  P. Box.  SCN9A mutations define primary erythermalgia as a neuropathic disorder of voltage gated sodium channels , 2005 .

[108]  M. Schwab,et al.  Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. , 2013, Pharmacology & therapeutics.

[109]  J. Lötsch,et al.  Meta-analysis of the relevance of the OPRM1 118A>G genetic variant for pain treatment , 2009, PAIN.

[110]  W. Berrettini,et al.  Pharmacogenetics of OPRM1 , 2014, Pharmacology Biochemistry and Behavior.

[111]  W. Willis.  The role of TRPV1 receptors in pain evoked by noxious thermal and chemical stimuli , 2009, Experimental Brain Research.

[112]  L. Sivilotti,et al.  A tetrodotoxin-resistant voltage-gated sodium channel expressed by sensory neurons , 1996, Nature.

[113]  D. Nelson,et al.  Cytochrome P450 nomenclature. , 1998, Methods in molecular biology.

[114]  Kwang-Hyeon Liu,et al.  The CYP3A4*18 Allele, the Most Frequent Coding Variant in Asian Populations, Does Not Significantly Affect the Midazolam Disposition in Heterozygous Individuals , 2007, Drug Metabolism and Disposition.

[115]  A. Tokunaga,et al.  5-HT2A receptor subtype is involved in the thermal hyperalgesic mechanism of serotonin in the periphery , 1998, Pain.

[116]  C. Meisel,et al.  Frequency of single nucleotide polymorphisms in the P‐glycoprotein drug transporter MDR1 gene in white subjects , 2001, Clinical pharmacology and therapeutics.

[117]  E. Tan,et al.  The influence of ATP-binding cassette sub-family B member -1 (ABCB1) genetic polymorphisms on acute and chronic pain after intrathecal morphine for caesarean section: a prospective cohort study. , 2010, International journal of obstetric anesthesia.

[118]  V. Ruiz-Velasco,et al.  Modulation of Ca2+ channels by heterologously expressed wild-type and mutant human micro-opioid receptors (hMORs) containing the A118G single-nucleotide polymorphism. , 2007, Journal of neurophysiology.

[119]  K. Ikeda,et al.  Association between 5-hydroxytryptamine 2A receptor gene polymorphism and postoperative analgesic requirements after major abdominal surgery , 2010, Neuroscience Letters.

[120]  K. Brøsen,et al.  Lack of Association of OPRM1 and ABCB1 Single‐Nucleotide Polymorphisms to Oxycodone Response in Postoperative Pain , 2012, Journal of clinical pharmacology.

[121]  C. Benedetti,et al.  Adult cancer pain. , 2010, Journal of the National Comprehensive Cancer Network : JNCCN.

[122]  F. Colpaert.  5-HT(1A) receptor activation: new molecular and neuroadaptive mechanisms of pain relief. , 2006, Current opinion in investigational drugs.

[123]  O. Matoušková,et al.  Impact of MDR1 genetic polymorphisms on postoperative piritramide analgesia. , 2013, Bratislavske lekarske listy.

[124]  Hussain Jafri,et al.  An SCN9A channelopathy causes congenital inability to experience pain , 2006, Nature.

[125]  G. Elmer,et al.  Heritability of nociception II. `Types' of nociception revealed by genetic correlation analysis , 1999, Pain.

[126]  Howard L McLeod,et al.  Pharmacogenomics--drug disposition, drug targets, and side effects. , 2003, The New England journal of medicine.

[127]  W. Clark,et al.  Preoperative Multidimensional Affect and Pain Survey (MAPS) scores predict postcolectomy analgesia requirement. , 2000, The Clinical journal of pain.

[128]  Yu-ting Chen,et al.  OPRM1 genetic polymorphisms are associated with the plasma nicotine metabolite cotinine concentration in methadone maintenance patients: a cross sectional study , 2012, Journal of Human Genetics.

[129]  S. Sereika,et al.  The Associations Between OPRM 1 and COMT Genotypes and Postoperative Pain, Opioid Use, and Opioid-Induced Sedation , 2013, Biological research for nursing.

[130]  S. Sereika,et al.  The Association of CYP2D6 Genotype and Postoperative Nausea and Vomiting in Orthopedic Trauma Patients , 2013, Biological research for nursing.

[131]  E. Bruera,et al.  Opioid switching: a systematic and critical review. , 2006, Cancer treatment reviews.

[132]  Marc Beaussier,et al.  Environmental and genetic factors associated with morphine response in the postoperative period , 2006, Clinical pharmacology and therapeutics.

[133]  D. Julius,et al.  The capsaicin receptor: a heat-activated ion channel in the pain pathway , 1997, Nature.

[134]  S. Tsai,et al.  Association study of two serotonin 1A receptor gene polymorphisms and fluoxetine treatment response in Chinese major depressive disorders , 2006, European Neuropsychopharmacology.

[135]  Shiou-Sheng Chen,et al.  Polymorphism of μ-Opioid Receptor Gene (OPRM1:c.118A>G) Might Not Protect against or Enhance Morphine-Induced Nausea or Vomiting , 2013, Pain research and treatment.

[136]  Gustavo Turecki,et al.  Impaired Repression at a 5-Hydroxytryptamine 1A Receptor Gene Polymorphism Associated with Major Depression and Suicide , 2003, The Journal of Neuroscience.

[137]  Jun He,et al.  CYP3A5*3 and CYP3A4*18 single nucleotide polymorphisms in a Chinese population. , 2005, Clinica chimica acta; international journal of clinical chemistry.

[138]  A. Rane,et al.  Patient-controlled analgesia (PCA) with codeine for postoperative pain relief in ten extensive metabolisers and one poor metaboliser of dextromethorphan. , 1995, British journal of clinical pharmacology.

[139]  L. Arendt-Nielsen,et al.  The hypoalgesic effect of tramadol in relation to CYP2D6 * , 1996, Clinical pharmacology and therapeutics.

[140]  Wei Zhang,et al.  CYP3A4*1G genetic polymorphism influences CYP3A activity and response to fentanyl in Chinese gynecologic patients , 2009, European Journal of Clinical Pharmacology.

[141]  H. Zhou,et al.  Association of CYP3A4*18B polymorphisms with the pharmacokinetics of cyclosporine in healthy subjects , 2007, Xenobiotica; the fate of foreign compounds in biological systems.

[142]  R. Baumgartner,et al.  The role of hydromorphone and OPRM1 in postoperative pain relief with hydrocodone. , 2013, Pain physician.

[143]  Guangyou Duan,et al.  A Single-nucleotide Polymorphism in SCN9A May Decrease Postoperative Pain Sensitivity in the General Population , 2013, Anesthesiology.

[144]  E. Bruera,et al.  Exploring joint effects of genes and the clinical efficacy of morphine for cancer pain: OPRM1 and COMT gene , 2007, PAIN.

[145]  A. Serretti,et al.  Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder , 2010, Molecular Psychiatry.

[146]  O. Levran,et al.  Search for genetic markers and functional variants involved in the development of opiate and cocaine addiction and treatment , 2010, Annals of the New York Academy of Sciences.

[147]  I. Sora,et al.  The mu opiate receptor as a candidate gene for pain: polymorphisms, variations in expression, nociception, and opiate responses. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[148]  M. Hayden,et al.  CYP2D6 Polymorphisms and Codeine Analgesia in Postpartum Pain Management: A Pilot Study , 2011, Therapeutic drug monitoring.

[149]  K. Candiotti,et al.  The impact of CYP2D6 genetic polymorphisms on postoperative morphine consumption. , 2009, Pain medicine.

[150]  I. Ulmanen,et al.  Kinetics of human soluble and membrane-bound catechol O-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme. , 1995, Biochemistry.

[151]  O. Matoušková,et al.  Tramadol efficacy in patients with postoperative pain in relation to CYP2D6 and MDR1 polymorphisms. , 2012, Bratislavske lekarske listy.

[152]  Teruhiko Yoshida,et al.  Haplotypes of CYP3A4 and their close linkage with CYP3A5 haplotypes in a Japanese population , 2004, Human mutation.